ArticleJAMA internal medicine2019

Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone: Cohort Study of FDA and Sponsor Communication, 2011-2017.

Peter Doshi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.